Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia
Sarah P. Short, Jumpei Kondo, Whitney G. Smalley-Freed, Haruna Takeda, Michael R. Dohn, Anne E. Powell, Robert H. Carnahan, Mary K. Washington, Manish Tripathi, D. Michael Payne, Nancy A. Jenkins, Neal G. Copeland, Robert J. Coffey, Albert B. Reynolds
Sarah P. Short, Jumpei Kondo, Whitney G. Smalley-Freed, Haruna Takeda, Michael R. Dohn, Anne E. Powell, Robert H. Carnahan, Mary K. Washington, Manish Tripathi, D. Michael Payne, Nancy A. Jenkins, Neal G. Copeland, Robert J. Coffey, Albert B. Reynolds
View: Text | PDF
Research Article Cell biology Oncology

p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia

  • Text
  • PDF
Abstract

p120-Catenin (p120) functions as a tumor suppressor in intestinal cancer, but the mechanism is unclear. Here, using conditional p120 knockout in Apc-sensitized mouse models of intestinal cancer, we have identified p120 as an “obligatory” haploinsufficient tumor suppressor. Whereas monoallelic loss of p120 was associated with a significant increase in tumor multiplicity, loss of both alleles was never observed in tumors from these mice. Moreover, forced ablation of the second allele did not further enhance tumorigenesis, but instead induced synthetic lethality in combination with Apc loss of heterozygosity. In tumor-derived organoid cultures, elimination of both p120 alleles resulted in caspase-3–dependent apoptosis that was blocked by inhibition of Rho kinase (ROCK). With ROCK inhibition, however, p120-ablated organoids exhibited a branching phenotype and a substantial increase in cell proliferation. Access to data from Sleeping Beauty mutagenesis screens afforded an opportunity to directly assess the tumorigenic impact of p120 haploinsufficiency relative to other candidate drivers. Remarkably, p120 ranked third among the 919 drivers identified. Cofactors α-catenin and epithelial cadherin (E-cadherin) were also among the highest scoring candidates, indicating a mechanism at the level of the intact complex that may play an important role at very early stages of of intestinal tumorigenesis while simultaneously restricting outright loss via synthetic lethality.

Authors

Sarah P. Short, Jumpei Kondo, Whitney G. Smalley-Freed, Haruna Takeda, Michael R. Dohn, Anne E. Powell, Robert H. Carnahan, Mary K. Washington, Manish Tripathi, D. Michael Payne, Nancy A. Jenkins, Neal G. Copeland, Robert J. Coffey, Albert B. Reynolds

×

Figure 2

Reduced p120 immunoreactivity at intestinal crypt base and in Apc-driven adenomas.

Options: View larger image (or click on image) Download as PowerPoint
Reduced p120 immunoreactivity at intestinal crypt base and in Apc-driven...
(A) Epithelial architecture and function in the small intestine (modified from Reya and Clevers, Nature 2005) (B) Immunolocalization of p120 and β-catenin and (C) β-catenin and Kaiso in the small intestine. Immunoreactivity in the crypt (bracket) is reduced for p120 and elevated for Kaiso as compared with villous compartment. Boxes represent area enlarged in Merge + Hoechst. Scale bars: 100 μm. (D) p120 Immunoreactivity is reduced in ApcMin/+ adenomatous tissue marked by upregulated β-catenin staining (arrowheads) relative to adjacent normal tissue (asterisks). Scale bars: 100 μm. (E) p120 and β-catenin immunoreactivity in representative Apc1638N/+ adenoma. Weak β-catenin signal is typical of Apc1638N/+. Adjacent normal tissue (asterisk). Scale bar: 100 μm. (F) Reduced p120 IHC staining in human familial adenomatous polyposis (FAP) samples. Images depict a single crypt microadenoma (first panel) and small macroadenoma (second panel, arrowheads). Normal tissue designated by arrows. Scale bar: 100 μm. (G) p120, β-catenin, and Kaiso immunoreactivity in a representative Lrig1CreERT2; Ctnnb1ΔEx3/+–derived adenoma (arrowhead). Scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts